RxDoctor Payments DataLook up a doctor →

Krishnan Chakravarthy

Pain Medicine · Temecula, CANPI 1043573488

Payments from drug & device makers

$1,936,923in general payments, 2019–2025

Across 2,158 payments — averaging $897.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$939K
  • Mesoblast, Inc.$431K
  • MML US, Inc.$275K
  • Abbott$214K
  • Vertos Medical, Inc.$34K
  • Bioness Inc$15K
  • plus $28K from 27 others
$35,380in research payments, 2019–2025

Across 4 payments — averaging $8844.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bioventus LLC$35K
  • Saluda Medical Americas, Inc.$62

What the payments were for

  • Consulting fees$257,37920%
  • Speaking & faculty fees$795,83263%
  • Travel & lodging$139,90211%
  • Food & beverage$52,5354%
  • Education$15,2981%
  • Entertainment$1950%
  • Ownership interest$9170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,936,923 in reported general payments places this provider in the 95th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$24,371
Medicare patients
64
Services billed
176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin44$1,322
Oxycodone Hcl18$299
Meloxicam12$58

Paid to pharmacies, not to this prescriber.

Other pain medicine in Temecula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →